Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Food Effect of QLS1410 in Healthy Adults and Hypertension
NCT07152444Phase 1Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Sep 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of QLS1410 in essential hypertension (5 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Incidence and severity of treatment emergent Adverse Events up to 1 month. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
QLS1410
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT07152444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07152444.